ABSTRACT
We carried out a population-based case-control study to evaluate the association between multiple sclerosis (MS) and headache. We had previously determined the incidence of MS during 1990-1999 in Catania, Sicily, identifying 155 incident MS patients; these subjects underwent a telephone interview using a standardized questionnaire for headache. Diagnosis and classification of headaches were made according to International Headache Society criteria (1988). A control group was selected from the general population through random digit dialling. One hundred and one (65.2%) MS patients, of the 155 identified, and 101 controls were screened for headaches. Fifty-eight (57.4%) MS patients and 38 (37.2%) controls fulfilled the diagnostic criteria of headache. A significant association between MS and headache was found with an adjusted odds ratio, estimated by logistic regression, of 2.18 (95% confidence interval 1.27, 3.93). Frequency of headaches in our MS population is higher than in the general population, supporting the hypothesis of a possible association between these two conditions.
Subject(s)
Headache/epidemiology , Multiple Sclerosis/epidemiology , Adult , Age Distribution , Age of Onset , Case-Control Studies , Comorbidity , Female , Humans , Male , Prevalence , Sex Distribution , Sicily/epidemiologyABSTRACT
OBJECTIVE: There exist controversial and discrepant results on the risk of spontaneous abortions and teratogenesis induced by interferon treatment in people with MS.Aim of this study is to evaluate risks of the administration of INFbeta related not only to the foetus, but also to children development up to 12-months developmental milestones. METHODS: The study design is retrospective with a follow-up of babies until 18-months of their life. Thirty-eight women out of 240 with MS followed-up at Clinic MS Center of the University Hospital of Catania, Italy became pregnant in the period june 1997-may 2006. Patients were grouped into three arms: in utero exposed to INFbeta, never treated and patients who discontinued INFbeta before starting conception. Pregnancy outcomes, birth weight, 12-month developmental milestones were collected with an ad hoc questionnaire. RESULTS: Newborns of in utero exposed to INFbeta patients were little smaller for birth weight (3079.6 +/- 313.3 g), but not statistically significant, if compared with the other groups. Developmental milestones appeared within the normal range in all groups. CONCLUSIONS: Our results were particularly favourable on pregnancy outcomes, because we observed only a smaller birth weight which was not detrimental for the further development of children. We believe that INFbeta therapy might not be considered to be a reason for interruption of an intact pregnancy once the drug has been discontinued until delivery.
Subject(s)
Immunologic Factors/adverse effects , Interferon-beta/adverse effects , Pregnancy Complications/chemically induced , Pregnancy Outcome , Adult , Analysis of Variance , Birth Weight/drug effects , Female , Follow-Up Studies , Humans , Infant , Multiple Sclerosis/drug therapy , Pregnancy , Pregnancy Complications/epidemiology , Retrospective Studies , Surveys and QuestionnairesABSTRACT
We evaluated the presence of IgA and IgG celiac disease-related antibodies in a sample of 217 patients with multiple sclerosis (MS) and in a sample of 200 controls not affected by neurological disorders. None of the 217 patients with MS presented IgG and IgA anti-gliadin, anti-endomysial antibodies, anti-tissue transglutaminase and anti-reticulin, whereas only one of the selected controls presented specific antibodies; this subject resulted to be effectively affected by celiac disease. Our data did not show an increased frequency of celiac disease among patients with MS.
